Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease thalassemia
Symptom C0029456|osteoporosis
Sentences 10
PubMedID- 25849944 The reported frequency of osteoporosis, in thalassemia mayor patients, despite adequate transfusion and iron chelation therapy, varies from 13.6% to 50% with an additional 45% affected by osteopenia .
PubMedID- 22581647 We conclude that circulating sclerostin is elevated in thalassemia patients with osteoporosis and correlated with their bmd, but it was not reduced post zoledronic acid administration.
PubMedID- 25002928 Uncontrolled erythropoiesis and progressive marrow expansion are other causes of osteoporosis in thalassemia major and intermedia patients.osteoporosis is a side effect of iron toxicity on osteoblasts and also deferoxamine, an iron chelator which is used in these patients.
PubMedID- 20694183 In a study by otrock et al,60 18 thalassemia patients with osteoporosis were given zol 4 mg iv every 3 months over a period of 12 months.
PubMedID- 20976089 osteoporosis in thalassaemia major (tm) represents a prominent cause of morbidity.
PubMedID- 25216685 Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (trpv1) channels.
PubMedID- 22778734 Subjects in low pubertal staging and short stature(<3% percentile) have significantly lower bone mass densities p < 0.001. conclusion.he prevalence of osteoporosis is high in patients with thalassemia major, possibly related to delayed puberty.
PubMedID- 24575552 osteoporosis in thalassemia major: an update and the i-cet 2013 recommendations for surveillance and treatment.
PubMedID- 23652868 In a previous study aimed at comparing dxa and quantitative computed tomography (qct), mylona and colleagues observed a strong difference in the prevalence of osteopenia and osteoporosis in patients with β-thalassemia according to the technique used.
PubMedID- 22966867 Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in beta-thalassaemia presenting with osteopenia-osteoporosis syndrome.

Page: 1